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∂ EL classification: C11; C15.Abstract
We consider the problem of assessing new and existing technologies for their cost-eﬀectiveness in
the case where data on both costs and eﬀects are available from a clinical trial, and we address it by
means of the cost-eﬀectiveness acceptability curve. The main diﬃculty in these analyses is that cost
data usually exhibit highly skew and heavy-tailed distributions, so that it can be extremely diﬃcult to
produce realistic probabilistic models for the underlying population distribution, and in particular to
model accurately the tail of the distribution, which is highly inﬂuential in estimating the population
mean. Here, in order to integrate the uncertainty about the model into the analysis of cost data
and into cost-eﬀectiveness analyses, we consider an approach based on Bayesian model averaging in
the particular case of weak prior informations about the unknown parameters of the diﬀerent models
involved in the procedure. The main consequence of this assumption is that the marginal densities
required by Bayesian model averaging are undetermined. However in accordance with the theory of
partial Bayes factors and in particular of fractional Bayes factors, we suggest replacing each marginal
density with a ratio of integrals, that can be eﬃciently computed via Path Sampling. The results in
terms of cost-eﬀectiveness are compared with those obtained with a semi-parametric approach that
does not require any assumption about the distribution of costs.
1I n troduction
The increasing burden on the budgets of health care providers has resulted in considerable interest in
assessing new and existing technologies for their clinical eﬀectiveness and cost-eﬀectiveness.
Suppose that we intend to compare two health care technologies T1 and T2 in a randomised controlled
trial, where data consist of the eﬀect eij and the cost cij of treatment i on patient j (i =1 ,2; j =
1,2,...,ni).
In order to assess if T2 is more cost-eﬀective than T1,w eneed to compare the expected eﬀects µ1 and
µ2 as well as the expected costs γ1 and γ2.I n particular, let ∆e = µ2 − µ1 and ∆c = γ2 − γ1 be the
eﬀect and cost diﬀerentials. Moreover, let K be a decision-maker’s willingness to pay coeﬃcient, that is
the units of money a decision maker is prepared to pay to obtain one unit of eﬀectiveness.
The primary measure of cost-eﬀectiveness of T2 relative to T1 is usually considered to be the net
monetary beneﬁt K∆e − ∆c (O’Hagan et al., 2000): T2 is cost-eﬀective relative to T1 if K∆e − ∆c > 0,
i.e. if in the plane of possible pairs of values of the population mean increments of eﬀect and cost, (∆e,∆c)
is below a sloping line of gradient K. This is usually referred as the Net Beneﬁt approach (Stinnett and
Mullahy, 1998), and inference about the net monetary beneﬁt is generally presented by means of a Cost-
Eﬀectiveness Acceptability Curve (CEAC), that plots the probability Q(K)=P (K∆e − ∆c > 0)that
2the net beneﬁt is positive against the coeﬃcient K (van Hout et al., 1994), which is rarely unambiguously
determined in practice. In this sense, a Bayesian approach is particularly natural, since no such probability
exists or has any meaning in frequentist statistics (O’Hagan et al., 2000).
Clearly these cost-eﬀectiveness analyses of clinical trial data rely on statistical models which describe
the distribution of costs and eﬀects and their interrelation across individuals in the trial, which are rather
diﬃcult to determine, mainly because cost data obtained for individual patients in health economic
studies typically exhibit highly skew and heavy tailed distributions. In fact, as discussed in O’Hagan
and Stevens (2002, 2003), non-parametric methods, such as those based on the asymptotic normality of
the sample mean or nonparametric bootstrapping, may be ineﬃcient for analising such data and their
justiﬁcation breaks down in small samples. See Dinh and Zhou (2006) for some recent developments
on such methods. On the other hand, parametric modelling may lead to more eﬃcient inference (see,
among others, Al and van Hout, 2000, O’Hagan and Stevens, 2001, 2002, Fryback et al., 2001) but is
dependent on the population distribution matching the model adequately. The main diﬃculty in this
sense, as pointed out for instance in Nixon and Thompson (2004) and Thompson and Nixon (2005), is
that the high skewness and kurtosis usually found in cost data imply that the population mean can be
very sensitive to the tail of the distribution, that might be diﬃcult to model accurately. One consequence
of this is that parametric models that ﬁt the data equally well can produce very diﬀerent answers;
conversely, in some cases models that ﬁt badly can give similar inferences to those that ﬁt well. For these
reasons, Thompson and Nixon (2005) recommend that the sensitivity of conclusions to the choice of the
model is always investigated, so that model uncertainty becomes a crucial aspect of analysing cost data.
Ad iﬀerent proposal for overcoming these diﬃculties can be found in Conigliani and Tancredi (2005a),
that suggested to model the bulk of the data and the tails separately, with a distribution composed of
ap iecewise constant density up to an unknown endpoint and a generalised Pareto distribution (GPD)
for the remaining tail data; this semi-parametric model, that is extremely ﬂexible and able to ﬁt data
set with very diﬀerent shapes, has been applied to cost-eﬀectiveness analyses in the simple case where
eﬀects are measured as binary outcomes in Conigliani and Tancredi (2005b), and to more general settings
in Conigliani and Tancredi (2008), where the results of the semi-parametric model are compared with
those obtained with Bayesian model averaging (BMA). Note that an approach based on BMA in this
setting is somehow in the spirit of the sensitivity analyses advocated by Thompson and Nixon (2005).
In fact, it requires the speciﬁcation of a set of plausible models for costs, but instead of studying how
the conclusions change with the diﬀerent models, it takes into account the inferences obtained with all
the models that have a non-zero posterior probability. Obviously the main diﬃculty of this approach is
the speciﬁcation of the set of plausible models, in the sense that it should include distributions with a
3wide range of shapes both for the bulk of data and for the tail. But another diﬃculty is represented by
the fact that Bayesian model averaging requires proper prior distributions for the unknown parameters
of the various models, even when there is not enough prior knowledge to elicit them.
Here, in order to focus the attention on the distribution of costs, we ﬁnd convenient to write the
distribution for a single observation xij =( eij,c ij)  under treatment Ti as
f (xij |θi,φ i)=f (cij |θi)f (eij |cij,φ i)
where f (cij |θi)i sthe unconditional distribution for the cost of patient j under Ti and f (eij |cij,φ i)i sthe
conditional distribution for the eﬀect on patient j under Ti given the cost cij, that we assume independent
on the parameter θi of the distribution of costs. And in order to integrate the uncertainty about the model
for costs into cost-eﬀectiveness analyses, we consider an approach based on Bayesian model averaging
in the particular case of weak prior informations for the unknown parameters of the diﬀerent models.
This is presented in details in Section 2, together with the problems caused by the assumption of non-
informative priors, namely the fact that the marginal densities required by BMA are undetermined. In
the same section we recall the theory of partial Bayes factors and in particular of fractional Bayes factors,
and we suggest computing the required posterior model probabilities by replacing each (undetermined)
marginal density with a ratio of integrals. In Section 3 we revise some of the numerical methods usually
applied in Bayesian statistics to obtain inferences based on integrals, and focus our attention on Path
sampling, a particularly ﬂexible and eﬃcient simulation method introduced by Gelman and Meng (1994,
1998) for the direct computation of ratios of marginal densities. In Section 4 the proposed methodology is
compared with the semi-parametric approach of Conigliani and Tancredi (2005a) in an empirical context.
A few concluding remarks are presented in the ﬁnal section.
2 Analysing cost data with Bayesian model averaging with weak
prior informations
Suppose that under each treatment group, instead of choosing a single parametric model for cost data,
we specify a set of plausible models M = {M1,M 2,...,Mk}.I nparticular, we assume that M is made of
the log-normal, gamma, Weibull, log-logistic, generalised Pareto and inverse Gaussian; the corresponding
probability density function and main summaries are shown in Table 1. Note that these distributions
are always positive and skewed to the right, and oﬀer a range of diﬀerent tail behaviours. Moreover,
we assume that all six distributions have ﬁnite ﬁrst and second moment (which requires a constraint for
the shape parameter of the log-logistic and the generalised Pareto), so that they can be re-parametrized
4Table 1: Single parametric models included in the BMA procedure
Pdf Mean Variance
Log − normal
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in terms of the mean cost γ and the variance σ2. Then the posterior marginal distribution of γ can
be obtained by Bayesian model averaging (Hoeting et al., 1999) as a mixture of its posterior marginal







and πl(γ,σ2)b erespectively the distribution of the cost data and
the prior distribution of the parameters under model Ml in M.M oreover, let π(Ml)b ethe prior model
probability of Ml, such that
k
l=1 π(Ml)=1. Then according to BMA the posterior marginal distribution








where the posterior distribution of the parameters under Ml and the posterior model probability of Ml,






















fl (c1,...,cn |γ,σ2)πl(γ,σ2)dγdσ2 (3)
respectively.
Note that this is more or less the setting of Conigliani and Tancredi (2008); in particular, they suggest
to re-parametrize all models in M in terms of the mean cost and the coeﬃcient of variation (i.e. the
ratio of the standard deviation to the mean), so that the unknown parameters have a clear meaning and
the same prior distribution can be introduced under the various models in M.
However Bayesian model averaging requires proper prior distributions for the unknown parameters
under the various models in M,e ven when there is not enough prior knowledge to elicit them. In fact,
5if the prior for γ and σ2 under model Ml is improper, i.e. deﬁned only up to an arbitrary constant,






πl(γ,σ2)dγdσ2 is itself a multiple of such constant (l =
1,...,k). Clearly this does not represent a problem for the computation of the posterior distribution of
the parameters under model Ml, given by (2), since the same prior distribution, and therefore the same
unknown constant, appears in the numerator and in the denominator of (2) and cancels out. Instead,
the posterior model probability for Ml,g iven by (3), depends not only on πl(γ,σ2), but also on the prior
distribution for γ and σ2 under the other models in M. And, as pointed out for instance in Berger
and Pericchi (1996), what appears to be the same parameter can have very diﬀerent interpretations, and
therefore diﬀerent prior distributions, under diﬀerent models. It follows that in (3) the diﬀerent unknown
constants do not cancel, and (3) cannot be computed.
Now, the fact that improper prior distributions result in undetermined marginal densities and repre-
sent a problem for computing posterior model probabilities, i.e. for Bayesian model selection, is a well
known fact and several suggestions can be found in the literature to overcome this diﬃculty, most of
which are based on the idea of training samples.
Formally, for each model Ml in M, divide the cost data c1,...,cn into two parts, c(m) and c(n−m),








;i nthe second step, taking this as a prior





















that clearly does not depend on an arbitrary constant if the prior distribution πl(γ,σ2)i simproper.
Note that this is the idea that lead to the deﬁnition of partial Bayes factors. There is, however, a
diﬃculty with the use of (4), namely the selection of the training sample c(m) from the data. To avoid
the arbitrariness of choosing a particular training sample, O’Hagan (1995) suggested instead the use of


























which motivated the deﬁnition of the fractional Bayes factor (O’Hagan, 1995).
Now going back to the problem of deriving the posterior model probabilities (3) required by (1)
when there is not enough prior knowledge to elicit proper prior distributions for γ and σ2, the above

























One last issue is worth a few considerations. The choice of the size of the training sample has
been widely discussed in the literature; see for instance O’Hagan (1995, 1997). One simple and obvious
guidance, that has proved to be reliable in a range of problems involving improper priors, is to consider
the minimal training sample, i.e. the smallest sample size needed to update an improper prior so as
to obtain a proper prior distribution. Here, if we consider an improper prior for γ and σ2,aminimal
training sample is any subset made of two observations, so that b =2 /n.
3C omputing posterior model probabilities via path sampling
Computing marginal densities, or equivalently normalising constants of probability models, is a funda-
mental computational problem for many statistical and scientiﬁc studies; for a review of the methods
more widely used in Bayesian statistics see, for instance, Smith et al. (1985), Smith (1991), Tanner
(1993), O’Hagan and Forster (2004), and the references therein; for comparisons of these methods in
Bayesian model selection see, for example, Rosenkrantz (1992), Kass and Raftery (1995), Raftery (1996).
Approximations of marginal densities for well behaved problems of modest dimensionality can be
obtained by a number of diﬀerent procedures; these include methods of analytic approximation, such as
Laplace’s method (De Bruijn, 1961; Tierney and Kadane, 1986), and numerical integration procedures,
such as adaptive Gaussian quadrature (Genz and Kass, 1993) and Bayesian quadrature (O’Hagan, 1991).
For complex models, however, the only methods available are those based on simulations.
Simulation-based procedures include Monte Carlo integration (Hammersley and Handscomb, 1979)
and importance sampling (Geweke, 1989); the idea is to learn about a complex probability distribution
by simulating a set of random numbers from it, or from an auxiliary distribution that approximates it. In
many ﬁelds, however, the complex probability systems encountered make these methods often unusable,
and more advanced and typically more eﬃcient simulation procedures are in common use. In particular,
since the advent of Markov chain Monte Carlo methods (Gelfand and Smith, 1990, Tanner and Wong,
1987), several procedures have been proposed to obtain estimates of marginal densities by sampling from
the posterior distribution of the parameters; work along this line includes Newton and Raftery (1994),
Gelfand and Dey (1994), Chib (1995), Chib and Jeliazkov (2001).
7Notice that the majority of the procedures we have referred to only produce approximations of one
integral at a time. In various applications however, as in the case of computing posterior model probabil-
ities via (5), the real interest is often not the magnitude of the integral, but rather ratios, or equivalently
diﬀerences of the logarithms. Moreover such methods can be particularly unstable when the integrand is
diﬀuse, as it is typically the case with the denominator of (5) for small b.I tfollows that in this setting
procedures for the direct approximation of ratios of integrals, such as the Bridge Sampling of Meng and
Wong (1996) and the Path Sampling of Gelman and Meng (1994, 1998), may be more appropriate.
Ad iﬀerent approach that leads to the direct approximation of ratios of marginal densities is related
to the specialized MCMC algorithms developed to handle problems involving inference about curves,
surfaces or images, where the dimension of the object of inference is not ﬁxed. Work along this line
includes the product-space approach of Carlin and Chib (1995) and the reversible jump MCMC method
of Green (1995). However both methods require the speciﬁcation of proper priors for the unknown
parameters, so that here we focus our attention on Path Sampling.
Thus, suppose we intend to compute the ratio of integrals (5) in order to obtain the posterior model
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8which represents the key formula for path sampling: λ(Ml) can be expressed as the integral over Ω of an




,o fafunction of the path.








for given ω, and to carry out the integration with respect to ω.I n par-
ticular, the latter is usually obtained by standard numerical integration, that requires the integrand to
be evaluated at a set of ﬁxed points ωr (r =1 ,...,N). Instead, the expected value is usually obtained by
simulation, i.e. by sampling values (γsr,σ2




for given ωr or, when this is not practical, with an iterative Markov chain Monte Carlo sampler. The




















where a1,...,aN is a set of weights.
Notice that an alternative to numerical integration is to evaluate the integral with respect to ω by
Monte Carlo importance sampling, by drawing ω1,ω 2,...,ωN randomly from an arbitrary density p(ω).
However this approach will typically be less eﬃcient and more computationally demanding than numerical
integration, that usually involves studying the function we are trying to integrate, and choosing the points
ωr in some sensible way. Moreover, recall that in our approach inference on the mean cost γ is based
on the posterior marginal distribution (1), that depends on the posterior distributions of γ and σ2 under
the diﬀerent models in M (as well as on the posterior model probabilities). And posterior summaries of




.I tfollows that we
ﬁnd working with a ﬁxed grid (such that ωN =1 )preferable.

















typically be diﬀuse for ωr close to b.I tfollows that (10) can be rather unstable for small values of b.F o r
this reason, we suggest computing (10) with an adaptive procedure of some kind, and in particular with
an adaptive Metropolis-Hastings algorithm.




, i.e. from the posterior distribution of γ
and σ2 under model Ml; this is a standard computational problem and can be usually solved by proposing
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Figure 1: Data from the low back pain trial




(r =1 ,...,N−1). By doing so, as the target density
becomes more diﬀuse, also the proposal distribution becomes more diﬀuse, and (10) does not suﬀer from
stability problems for small values of b.
4 Analysis of the Low Back Pain Trial data
We present an example using a study on low back pain (Jarvik et al., 2003). A total of 380 patients
(out of which 328 were included in the health economic evaluation) were randomised in a 1:1 ratio to
investigation by standard X-ray investigation and rapid magnetic resonance imaging (rMRI), and were
followed for 12 months. Aim of the trial was to investigate whether rMRI would allow better diagnosis and
treatment, or lead to unnecessary treatment without improvement in symptoms. The primary clinical
endpoint was the change from baseline of the modiﬁed Roland back pain score (Patrick et al., 1995),
while the primary economic endpoint was the total health care cost (in US$).
The data are shown in Figure 1. Under both treatments the eﬀects as well the marginal conditional
10Table 2: Low back pain trial: sample descriptive statistics of X-ray costs and rMRI costs
Xr a y rMRI
sample size 166 162
mean 1515 2187














distributions of the eﬀects are apparently well represented by a normal distribution, so that we assume






and the overall mean eﬀect can be written as µi = βi + δiγi. Instead, the distribution of costs is clearly
highly skew and heavy-tailed, and this fact is conﬁrmed also by the sample summaries shown in Table 2.
We now apply the approach of Section 2 and Section 3 to this data set, assuming for both treatment
groups equal prior model probabilities for the six distributions in M, and introducing the standard
non-informative prior πl(γ,σ2) ∝
1
σ2 for the unknown parameters γ and σ2 under each model in M
(l =1 ,...,k). In particular, we computed the ratios (5) required by the posterior model probabilities (6)
via Path Sampling, applying the trapezoidal rule on a grid of N=10 points for integrating with respect
to ω, and with the adaptive Metropolis-Hastings algorithm outlined in the previous section sampling




(r =1 ,...,N). As proposal distributions for γ and σ2 we
used two independent skew-t distributions, that turned out to be ﬂexible and (when necessary) heavy





became more diﬀuse. The results are presented in Table 3 and Table 4 for
the individual mean costs γ1 and γ2 respectively, and in Table 5 for the cost diﬀerential ∆c and eﬀect
diﬀerential ∆e.
Note that Table 3 and Table 4 also show the posterior summaries that we obtain if, instead of applying
Bayesian model averaging, we model the X-ray costs and the rMRI costs with the single parametric models
included in M, and with the mixture model of Conigliani and Tancredi (2005a). In fact, the standard
parametric analysis is extremely helpfull to illustrate how sensitive inference about cost-eﬀectiveness is
11Table 3: Low back pain trial: posterior summaries of mean X-ray cost
Model for costs E(γ1 |c11...c1n1 ) PCI0.95 π (Ml1 |c11...c1n1 )
Log-normal 1603 1529;1678 0
Gamma 1487 1438;1540 0
Weibull 1548 1447;1658 0
Loglogistic 1199 1132;1266 1
GPD 1496 1423;1579 0
Inverse Gaussian 1329 1281;1376 0
BMA 1199 1132;1266 -
Mixture model 1555 1301;1837 -
Table 4: Low back pain trial: posterior summaries of mean rMRI cost
Model for costs E(γ2 |c21...c2n2 ) PCI0.95 π (Ml2 |c21...c2n2 )
Log-normal 2022 1941;2105 0
Gamma 2159 2079;2233 0.86
Weibull 2058 1914;2209 0
Loglogistic 1362 1290;1445 0.14
GPD 2019 1904;2148 0
Inverse Gaussian 2104 2036;2172 0
BMA 2052 1326;2230 -
Mixture model 2377 1840;3051 -
to the choice of the model for costs, and how an approach based on Bayesian model averaging can be
used to overcome this problem. On the other hand, although in the applications at least one of the
distributions in M will have a positive posterior model probability, there is no guarantee that either of
them ﬁt the data well. For this reason we ﬁnd interesting to compare the results obtained with Bayesian
model averaging also with those obtained with the mixture model of Conigliani and Tancredi (2005a),
that does not require any assumption about the distribution of costs, and allows inference on the mean
cost to take account of the uncertainty about the tail; details of the model and of the prior assumptions
can be found in Tancredi et al. (2006) and in Conigliani and Tancredi (2005a, 2008).
Consider ﬁrst the results of the standard parametric analysis. According to the posterior model
probabilities shown in Table 3 and Table 4, while in the X-ray group the data deﬁnitely support the
12Table 5: Low back pain trial: posterior summaries of cost diﬀerential and eﬀect diﬀerential
Model for costs E(∆c |D) PCI0.95 P(∆c> 0|D) E(∆e |D) PCI0.95 P(∆e> 0|D)
BMA 853 116;1056 1.00 -0.12 -1.6;1.3 0.43
Mixture 822 212;1538 1.00 0.02 -1.4;1.5 0.51
log-logistic distribution, in the rMRI group plausible models are the gamma (with the highest posterior
probability) and the log-logistic. These two models, however, lead to rather diﬀerent posterior summaries
of the mean rMRI cost, and therefore to rather diﬀerent conclusions in terms of the cost diﬀerential ∆c.
In fact, both models suggest that there is evidence of a higher mean cost in the rMRI group, but the
strengh of this evidence depends on which model we assume for the data. At one end, if we assume the
log-logistic for X-ray costs and the log-logistic for rMRI costs, for the mean cost diﬀerence we obtain a
point estimate of $163, and a posterior credible interval that includes the value ∆c =0 .A tthe other end,
if we assume the log-logistic for X-ray costs and the gamma for rMRI costs, for the mean cost diﬀerence
we obtain a point estimate of $960, and a posterior credible interval all on the positive line. It follows that
in terms of the analysis of costs and of cost-eﬀectiveness here diﬀerent models with non-zero posterior
probability produce rather diﬀerent results. And this is exactly a situation where it seems appropriate to
apply model averaging: instead of choosing between diﬀerent models, and then studying the sensitivity
of the conclusions in terms of cost-eﬀectiveness, model averaging takes into account all models which are
plausible for the data. Notice that in the particular study we are presenting, taking into account both
the gamma and the log-logistic distribution for rMRI costs results is a rather wide credible interval for
γ2:w ith respect to the interval obtained under the gamma model, the one obtained with BMA includes
also smaller values of γ2, that receive a positive posterior probability under the log-logistic model.
Consider now the comparison between the results of Bayesian model averaging and those obtained
with the mixture model of Conigliani and Tancredi (2005a). Looking ﬁrst at Table 3 and Table 4 we
notice that the point estimates of γ1 and γ2 obtained with the mixture model are higher than those
obtained with BMA, and the posterior credible intervals for γ1 and γ2 obtained with the mixture model
are wider than those obtained with BMA, so that under both treatment groups the mixture model seems
to give more weight to the upper tail of the cost distribution than any of the models included in M. Then
looking at Table 5 and at the two Cost-Eﬀectiveness Acceptability Curves in Figure 2, we see that also in
terms of cost-eﬀectiveness the two approaches lead to diﬀerent conclusions. In particular, although the
point estimates of ∆c and the probability that ∆c > 0 are nearly identical (as a consequence of the fact
that BMA underestimates the mean costs with respect to the mixture model under both treatments), the


























Figure 2: Low back pain trial: cost-eﬀectiveness acceptability curves
probability Q(K) that rMRI is cost-eﬀective is always lower under BMA than under the mixture model.
And if we look at the values of K where Q(K)i sa tl east 0.5, we ﬁnd K ≥ $30.000 under the mixture
model, while no such values of K exist under BMA. As pointed out in Conigliani and Tancredi (2008), in
such cases is very diﬃcult to decide which results one should believe, since these diﬀerences are mainly
related to the way the two methods deal with model uncertainty. This issue will be addressed further in
the ﬁnal Section.
5D iscussion
Most of the recent literature on cost-eﬀectiveness analyses of clinical trial data agrees that inferences are
signiﬁcally sensitive to the choice of the model for costs, and especially to how the upper tail of the cost
distribution beyond the observed data is modelled. The proposal of Conigliani and Tancredi (2005a) to
overcome this problem combines the semi-parametric approach to density estimation based on mixture
models and the semi-parametric approach to tail estimation based on extreme value theory; the result is
av ery ﬂexible model able to ﬁt data set with very diﬀerent shapes both in the bulk of data and in the tail,
14but there is a price to pay for so much ﬂexibility in terms of precision and eﬃciency of the corresponding
inferences.
In this paper we have considered an approach based on Bayesian model averaging, that is in the spirit
of the sensitivity analyses advocated by Thompson and Nixon (2005). It requires the speciﬁcation of a
set M of plausible models for cost data, but instead of studying how the conclusions change with the
diﬀerent models, it takes into account the inferences obtained with all the models in M that have a
non-zero posterior probability.
An approach based on Bayesian model averaging for cost-eﬀectiveness analyses in health economics
wasa lready proposed in Conigliani and Tancredi (2008), but it involved proper prior distributions for
the unknown parameters of the diﬀerent parametric models. Here we have considered the particular
case of weak prior informations, and the main consequence of this assumption is that standard Bayesian
model averaging cannot be applied. However in accordance with the theory fractional Bayes factors, we
have introduced a new procedure that can deal with improper priors. The computational issues that we
encountered were dealt with Path Sampling together with an adaptive Metropolis-Hastings algorithm.
We believe that a BMA type procedure that can be applied even when there is not enough prior
knowledge to elicit proper prior distributions for the parameters is particularly relevant especially in
a setting like this, where it is diﬃcult to determine plausible statistical models. In this sense, the
present approach is closer to the semi-parametric approach of Conigliani and Tancredi (2005a), that
does not require any assumption about the distribution of costs. However even if a priori we are not
introducing any informations, the speciﬁcation of the set M has nevertheless the eﬀect of reducing the
model uncertainty. It follows that Bayesian model averaging will generally lead to smaller intervals than
the semi-parametric approach, but the characteristics of these intervals signiﬁcantly depends on which
models are included in the procedure, so that particular care should be devoted to specifying M.
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